<DOC>
	<DOCNO>NCT02316002</DOCNO>
	<brief_summary>The main purpose study see well experimental drug pembrolizumab ( MK-3475 ) work people oligometastatic NSCLC already treatment disease . All patient receive 200 mg pembrolizumab intravenously Day 1 21-day cycle . Patients receive study drug 8 cycle , disease well study doctor think benefit patient may receive pembrolizumab 8 cycle .</brief_summary>
	<brief_title>Phase II Study Pembrolizumab After Curative Intent Treatment Oligometastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Provide write informed consent trial . 18 year age day sign informed consent . Completion definitive therapy 412 week prior enrollment . There specific limitation treatment modality use definitive setting ( e.g . use adjuvant chemotherapy acceptable ) , treatment must complete least 4 week prior enrollment . Provision tissue archival tissue sample newly obtain core excisional biopsy tumor lesion . 1 . Tumor tissue may diagnostic biopsy portion surgical specimen , surgery component definitive intent therapy . 2 . Formalin fix paraffin embed ( FFPE ) tissue sample acceptable ; fine needle aspirate , frozen sample , plastic embed sample , cell block , clot , bone , bone marrow cytologic specimen acceptable IHC analysis . 3 . It recommend FFPE block section fresh ( within 7 day section send PDL1 analysis ) onto positively charge slide ; slide store ship ( store upon receipt Qualtek ) 28C dark . 4 . Recommended fixation time sample 24 hour 48 hour 10 % neutral buffer formalin . Performance status 0 1 ECOG Performance Scale . Adequate organ function , screen lab perform within 10 day treatment initiation . Absolute neutrophil count 1,250 /mcL Product : Pembrolizumab Protocol/Amendment No . : 09/19/2014 10 ( ANC ) Platelets 100,000 / mcL Hemoglobin 9 g/dL ≥5.6 mmol/L Renal Serum creatinine OR Measured calculateda creatinine clearance ( GFR also use place creatinine CrCl ) ≤1.5 X upper limit normal ( ULN ) OR 50 mL/min subject creatinine level &gt; 1.5 X institutional ULN Hepatic Serum total bilirubin 1.5 X ULN OR Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN AST ( SGOT ) ALT ( SGPT ) 2.5 X ULN OR 5 X ULN subject liver metastasis aCreatinine clearance calculate per institutional standard . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity duration study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . Male subject partner woman childbearing potential willing use 2 method birth control , surgically sterile abstain heterosexual activity duration study 120 day last dose study medication . Currently participate participate study investigational agent use investigational device within 4 week first dose treatment . Diagnosis immunodeficiency exposure systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment ( Nasal oral inhaler permissible ) . Prior monoclonal antibody within 4 week prior study Day 1 individual recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior Day 1 drug administration study inability recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy alopecia exception criterion may qualify study . Note : If subject major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . Known additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , noninvasive bladder tumor , situ cervical cancer Known untreated central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy exception rule . Subjects require intermittent use bronchodilator local steroid injection exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . Evidence preexist interstitial lung disease active , noninfectious pneumonitis . Active infection require systemic therapy IV antibiotic History current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Known psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Known history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Known active Hepatitis B ( e.g. , HBsAg positive HBV DNA detectable ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . Receipt live vaccine within 30 day prior first dose trial treatment . Progressive disease sit new metastasis definitive therapy oligometastatic disease . Completion definitive therapy oligometastatic disease great 12 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>